Central India AYUSH Drugs Manufacturers Association vs. State of Maharashtra is a landmark judgment delivered by the Bombay High Court on September 28, 2016, establishing the statutory supremacy of Central regulatory provisions under Chapter IVA of the Drugs and Cosmetics Act, 1940 over conflicting state executive directives regarding the manufacture and testing of Ayurvedic and Unani medicines.
Background of the Dispute and Parties Involved
Writ Petition No. 6360 of 2015 was instituted before the Nagpur Bench of the Bombay High Court by the Central India AYUSH Drugs Manufacturers Association, represented through its Honorary Secretary Vijay Kumar Sharma and operating through Shree Baidyanath Ayurved Private Limited on Great Nag Road, Nagpur. The petitioner association represented numerous licensed manufacturers of traditional Ayurvedic, Siddha, and Unani pharmaceutical formulations across Central India.
The litigation was brought against the State of Maharashtra, through its Department of Medical Education and Drugs, and the Commissioner of the Food and Drug Administration (FDA) in Mumbai. The manufacturers challenged restrictive state circulars and conditions that imposed testing mandates and inspection regimes outside the framework established by the Central Parliament.
The petitioner contended that the state regulatory authorities exceeded their statutory competence by creating additional bureaucratic impediments that disrupted the legitimate production and interstate commercial distribution of standardized herbal drugs.
Statutory Framework Under Chapter IVA of the Drugs and Cosmetics Act, 1940
A Division Bench comprising Justice B.P. Dharmadhikari and Justice A.S. Chandurkar analyzed the statutory distribution of regulatory authority between the Union Government and state administrations:
- Exclusive Legislative Scope of Chapter IVA: The Parliament enacted Chapter IVA specifically to govern the manufacture, standardisation, labelling, and sale of Ayurvedic, Siddha, and Unani drugs across India.
- Rule-Making Authority Under Section 33N: The statutory power to formulate rules, prescribe standards of identity, purity, and strength, and establish mandatory testing protocols is vested in the Central Government after consulting the Ayurvedic, Siddha and Unani Drugs Technical Advisory Board (ASUDTAB).
- State Enforcement Mandate: State licensing authorities operate as enforcement agencies bound strictly to the standards and procedural conditions promulgated by Central rules.
The High Court scrutinized whether state authorities possessed delegated authority to introduce local conditions that altered Central regulatory norms.
Judicial Review of State Executive Orders and Administrative Discretion
The Division Bench examined the validity of executive instructions issued by the Maharashtra FDA Commissioner:
- Doctrine of Ultra Vires: Executive instructions cannot travel beyond or contradict parent statutory enactments and governing delegated rules.
- Uniform National Standards: Traditional medicines require uniform quality benchmarks across states to protect consumer welfare while facilitating domestic trade.
- Protection of Licensed Manufacturers: Units holding valid manufacturing licenses under Form 25D of the Drugs and Cosmetics Rules cannot be subjected to extraneous compliance conditions without statutory backing.
- Scientific Consultative Safeguards: Any alteration in testing criteria must emanate from formal consultations with statutory scientific advisory boards rather than unilateral administrative decrees.
Ruling of the Nagpur Bench on State Regulatory Boundaries
The Bombay High Court allowed the writ petition and quashed the contested state directives. The court held that while state regulators hold vital inspection duties to prevent counterfeit or adulterated formulations, they cannot impose novel regulatory conditions not authorized by the Central enactment.
State enforcement agencies under the Drugs and Cosmetics Act must execute statutory mandates within the strict boundaries established by Parliament and Central rules; executive circulars that impose additional compliance burdens without statutory sanction are legally unsustainable.
The judgment reaffirmed that regulatory consistency is essential for supporting industrial compliance while safeguarding public health. Transparent administrative processes align closely with accessible legal remedies and justice across healthcare sectors in India.
Impact on Traditional Medicine Regulation and Administrative Law
The ruling in Central India AYUSH Drugs Manufacturers Association aligns with established administrative jurisprudence on executive competence, reflecting principles emphasized in judicial review of administrative actions where courts firmly invalidated executive overreach.
Key principles established by the Bombay High Court include:
- Statutory Primacy: Central rules framed under Section 33N govern traditional pharmaceutical manufacturing across all Indian states.
- Invalidation of Unauthorized Circulars: State FDA circulars creating non-statutory compliance hurdles are null and void.
- Protection of Interstate Commerce: National regulatory uniformity prevents arbitrary state-level trade barriers for herbal medicines.
- Institutional Expertise: Changes to drug testing standards require formal scientific evaluation by designated statutory advisory bodies.
Compliance Strategies for Pharmaceutical Manufacturers
Ayurvedic drug manufacturers must maintain stringent internal quality controls compliant with Schedule T of the Drugs and Cosmetics Rules, covering Good Manufacturing Practices (GMP). When state authorities attempt to impose extra-statutory testing requirements, licensed enterprises can rely on High Court precedents to protect their commercial rights.
Understanding statutory boundaries empowers pharmaceutical associations to challenge administrative overreach effectively while maintaining rigorous consumer safety standards in Ayurvedic medicine manufacturing.
Regulatory Standards and Quality Assurance in Ayurvedic Drug Production
Manufacturers of Ayurvedic, Siddha, and Unani drugs operate under stringent technical guidelines defined by the Pharmacopoeia Commission for Indian Medicine and Homoeopathy (PCIM&H):
- Raw Material Authentication: Botanical ingredients must undergo rigorous botanical and chemical identification to verify authenticity and prevent contamination.
- Heavy Metal and Microbial Limits: Finished formulations must comply strictly with permissible limits for heavy metals, aflatoxins, and pesticide residues established by Central pharmacopoeial monographs.
- Stability and Shelf-Life Testing: Production units are obligated to conduct accelerated stability studies to guarantee therapeutic potency throughout the stated shelf life.
- Standard Operating Procedures: Facilities must implement documented sanitation, batch processing, and storage protocols to retain statutory licensing validity.
Legal Recourse for Licensed Drug Units Facing Arbitrary Executive Action
When state drug controllers issue executive circulars that depart from Central norms, affected manufacturers possess clear constitutional avenues of relief. Invoking writ jurisdiction under Article 226 of the Constitution allows manufacturers to seek mandamus against unauthorized inspections and obtain declarations upholding their statutory licenses.
Maintaining organized batch records and analytical certificates ensures that enterprises remain insulated against unjustified administrative sanctions while preserving commercial reputation across domestic and global markets.